MDXG News and Press, MiMedx Group Inc From 02/28/22

MiMedx Group press release (NASDAQ:MDXG): Q4 GAAP EPS of $0.01 beats by $0.04. Revenue of $67.29M (-1.1% Y/Y) beats by $3.6M. For further details see: MiMedx Group GAAP EPS of $0.01 beats by $0.04, revenue of $67.29M beats by $3.6M

Fourth Quarter Net Sales of $67.4 M illion and Full Year 2021 Net Sales of $258.6 M illion; Reflects a Double-Digit Revenue Increase in the Company's Continuing Portfolio of Products Vibrant Commercial Business is Funding New Product Development Initiativ...

ACAD,ACHC,AGM,AMBA,AMRC,OTCPK:AOIFF,APLS,APPF,APTS,ARCT,ARDX,ASXC,ATRA,AVIR,AY,BANX,BIGC,BLFS,BLNK,BRMK,CAPL,CLDX,CO,CSR,CSTL,DAR,DDD,DNMR,DVAX,ENDP,EVA,FATE,FGEN,FRPT,FSK,GAIA,GDRX,GMRE,GOEV,GPOR,GRPN,HHC,HPQ,HRTX,ICAD,KD,LAZR,LCID,MBI,MDXG,MRTX,NKTR,NMFC,NVAX,NVEE,OCUL,OKE,ONTF,OTIC,PDCE,PG...

Use of MIMEDX PURION ® Processed DHACM Provided Improved Clinical Benefits, Shorter Average Length of Treatment and Increased Quality-Adjusted Life Years MARIETTA, Ga., Feb. 16, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the ȁ...

MARIETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the fourth quarter ended Decemb...

MIMEDX Primed to Commence Pivotal Phase 3 Clinical Study Program of micronized dehydrated Human Amnion Chorion Membrane (mdHACM) in Knee Osteoarthritis (KOA), Targeting Potential Late-2026 Commercial Launch Double-Digit Growth Objective in 2022 to be Driven by Treatment Transfor...

MARIETTA, Ga., Jan. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Offi...

MARIETTA, Ga., Dec. 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial ...

Ahead of the company’s virtual Investor Day taking place at 9:00 a.m. ET today, MiMedx Group (NASDAQ:MDXG) has revised its guidance for adjusted net sales for fiscal 2021 to $253M – $258M from the previously announced projection of $245M – $255M. For fiscal 2020, the comp...

Company to Share Probability Values from its Knee Osteoarthritis (KOA) Study; Analyses Conducted Support Confidence in Initiation of Confirmatory Phase 3 Trials in 2022 Commercial Business Strategy Demonstrates Sustainable Double-digit Growth Potential in Multiple Underpenetrate...